Surya A. Reis

Surya A. Reis

Auto-generated profile, based on publicly available information

Surya A. Reis

Department of Neurology, Massachusetts General Hospital, Chemical Neurobiology Lab, and Center for Genomic Medicine, Harvard Medical School, Boston, MA 02114, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
IHIsrael Hernandez
Israel Hernandez
GLGabriel Luna
Gabriel Luna
JRJennifer N. Rauch
Jennifer N. Rauch
SRSurya A. Reis
Surya A. Reis
MGMichel Giroux
Michel Giroux
KKKenneth S. Kosik
Kenneth S. Kosik
Targeting farnesylation of Rhes induces lysosomal-mediated tau degradation and reduces tau pathology in mice with tauopathy.

2 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
KWKaris Will
Karis Will
SMSergio Lázaro Martínez
Sergio Lázaro Martínez
SRSurya A. Reis
Surya A. Reis
SHStephen J. Haggarty
Stephen J. Haggarty
N,N -dimethyltryptamine (DMT) is a serotonergic psychedelic with a history of ethnobotanical use and emerging clinical efficacy for neuropsychiatric disorders. Following Julius Axelrod’s pioneering studies showing DMT production in human tissues, DMT has been proposed as an endogenous neuromodulator because it is a serotonin 2A receptor (5-HT 2A R) agonist. However, the DMT-producing enzyme, indolethylamine N -methyltransferase (INMT), has not been characterized at the protein level in the human central nervous system. Here, we validated an anti-INMT antibody and used immunocytochemistry to show that INMT localizes in close proximity to other DMT biosynthetic enzymes near the cytosolic face of the cis -Golgi network in human induced pluripotent stem cell-derived neurons, with immunoreactivity observed across multiple neuronal Golgi phenotypes. Notably, both DMT-like and 5-HT 2A R immunoreactivity also partially localized in close proximity to the Golgi apparatus. Our results establish the first protein-level characterization of INMT in human neurons and identify the cis -Golgi network as a candidate microdomain for psychedelic tryptamine biosynthesis. We propose that INMT catalytic activity at the cis -Golgi network creates an enriched region of membrane-permeable psychedelic tryptamines that can access an intracellular 5-HT 2A R pool. These findings provide new tools and insights that can inform efforts to understand the mechanism of action of psychedelics under clinical investigation and to target endogenous tryptamines therapeutically. GRAPHICAL